The Salk approach, tested in a mouse model, points to cheaper and more effective treatments for humans
For most people with hemophilia B, whose bodies can’t properly form blood clots, constant injections to replenish their clotting factors are a way of life. But now, Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor. The finding, published in the journal Cell Reports on May 1, 2018, could drastically change what it means to be diagnosed with hemophilia B, and could pave the way toward similar treatments for other, related genetic disorders.
Hemophilia B is caused by defects in the gene for a protein called clotting factor IX (FIX). Hemophiliacs may make reduced amounts of the protein, or lack a functional version altogether, leading to life-threatening delays in blood clotting. Currently, patients are treated with injections—as often as a few times a week—containing FIX made in animal cells and then purified. But the approach is expensive, time-consuming and can become less effective over time.
Recently, Salk scientists developed a new approach, treating mice genetically engineered to have hemophilia B with strands of messenger RNA encoding the FIX gene. Like the standard treatment, however, this required repeat injections each time levels of the messenger RNA ran low. So the scientists wanted to try a more permanent approach: transplanting healthy liver cells, capable of producing FIX, into patients.
“The appeal of a cell-based approach is that you minimize the number of treatments that a patient needs,” says Suvasini Ramaswamy, a former Salk research associate in the Verma lab and first author of the new paper. “Rather than constant injections, you can do this in one shot.”
Since donor livers are often in short-supply, the researchers instead turned to stem-cell strategies to produce the healthy liver cells. They collected blood samples from two human patients with severe hemophilia B, who are unable to produce FIX. Then, in the lab, they reprogrammed the cells into induced pluripotent stem cells (iPSCs), which have the capability to turn into many other cell types, including liver. Using CRISPR/Cas9, a tool that can alter genes, they then repaired the mutations in each patient’s FIX gene. Finally, they coaxed those repaired cells to develop into liver precursor cells called hepatocyte-like cells (HLCs) and transplanted them into mice with hemophilia B.
Rather than perform surgery on hemophilic mice—a risky undertaking when their blood can’t always clot—the team transplanted the HLCs through the spleen to distribute the cells uniformly in the liver.
Not only did the new HLCs produce FIX, but they produced enough of the protein to allow the mice to form normal blood clots, and the cells continued to survive—and produce FIX—for at least a year after the transplantation.
In people with hemophilia, using their own cells to generate healthy HLCs, then transplanting them back into their bodies, could help avoid the immune complications that often accompany cell therapies. But more work is needed to translate the findings to the clinic.
“A lot of things have to happen before this can go into humans,” says Ramaswamy.
Already, she adds, the work demonstrates the value in combining stem-cell reprogramming and new gene-modifying approaches to treat genetic diseases.
The Latest on: Hemophilia B
via Google News
The Latest on: Hemophilia B
- The global bleeding disorders therapeutics market at a CAGR of almost 7% during the forecast periodon November 13, 2019 at 12:38 am
utm_source=GNW Our report also provides a detailed analysis of the market in Asia, Europe, North America, and ROW. In 2019, the Hemophilia A segment had a significant market share, and this trend is ...
- Global Bleeding Disorders Therapeutics Market 2020-2024 | Evolving Opportunities with Baxter International Inc. & Bayer AG | Technavioon November 11, 2019 at 4:10 pm
Hemophilia B, Von Willebrand disease, and Other disorders) and geography (North America, Europe, Asia, and ROW) 2020-2024". The market is driven by rising initiatives to increase awareness about ...
- Bleeding Disorders Treatment Market Overview by Share, Size, Industry Players, Revenue And Product Demand Till 2019-2024on November 11, 2019 at 3:48 am
Based on type segmentation it covers hemophilia A, hemophilia B, von willebrand disease, others. The Global Bleeding Disorders Treatment Market on geographic segmentation covers various regions such ...
- Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Updateon November 7, 2019 at 4:00 am
"We presented final MarzAA Phase 2 clinical data that clearly demonstrated the potential for subcutaneously (SQ) dosed MarzAA as a prophylactic treatment for hemophilia A or B patients with inhibitors ...
- 3 innovative rare disease drugs showcased at CIIEon November 6, 2019 at 11:59 pm
The three drugs treat Fabry disease, hemophilia B, and mucopolysaccharidosis, a rare metabolic disorder caused by the absence or malfunctioning of lysosomal enzymes. All three were the first to be ...
- Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meetingon November 6, 2019 at 6:00 am
B.Ch., Ph.D., Head of Research and Development ... designed to assess the safety and tolerability of SB-525 gene therapy in patients with severe hemophilia A. SB-525 was administered to 11 patients in ...
- Global Knee Replacement Market 2020-2024| Evolving Opportunities with B. Braun Melsungen AG and Conformis Inc. | Technavioon November 6, 2019 at 5:50 am
Number of people with conditions such as bone dysplasia, hemophilia, rheumatoid arthritis ... Buy 2 Technavio reports and get the third for free. B. Braun Melsungen AG is headquartered in Germany and ...
- Bleeding Disorders Treatment Market Size Analysis, Future Growth Insights, Share Value, Leading Players and Global Industry Trends By 2023on November 6, 2019 at 12:22 am
Bleeding Disorders Treatment Market Share Analysis, Growth and Trends by Type (Hemophilia A, Hemophilia B), Drug Class (Plasma-Derived Coagulation Factor Concentrates Market), Treatment (Desmopressin, ...
- Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028on November 1, 2019 at 6:38 pm
New York, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028" - ...
via Bing News